Literature DB >> 7515931

Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1.

T C VanCott1, F R Bethke, V R Polonis, M K Gorny, S Zolla-Pazner, R R Redfield, D L Birx.   

Abstract

mAbs specific for the V3 loop of HIV-1 are capable of neutralizing laboratory strains of HIV-1 in vitro. In this report we use surface plasmon resonance and biosensor technology to demonstrate that the ability of V3-specific mAbs to neutralize HIV-1(MN) correlated with the dissociation rate constant of the homologous mAb-gp120 binding interaction. mAbs capable of binding diverse strains of gp120 with similar association rate constants exhibited marked differences in the dissociation rate. The dissociation rate, and not the association rate, was found to be predictive of the neutralization capacity of the mAb. Furthermore, synthetic peptides corresponding to the V3 loop of HIV-1(IIIB, MN) yielded quantitatively similar binding kinetic profiles abrogating the need for purified recombinant gp120 protein and potentially facilitating the screening of more diverse isolates. Biosensor immobilized V3 peptides were found to mimic their conformational structure in solution. This offers advantages to peptides studied by ELISA where some degree of denaturation and masking of epitopes can occur upon adsorption of peptides to plastic surfaces. The impact of amino acid substitutions within epitopes on subsequent mAb binding was dissected by observing alterations in dissociation rates. The technique provides rapid kinetic analyses of V3 Ab binding interactions with diverse V3 sequences, facilitating the efficient screening and selection of those most likely to possess the broadest and most potent HIV-1 neutralizing potentials.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515931

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses.

Authors:  N McCloskey; M W Turner; P Steffner; R Owens; D Goldblatt
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

4.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Authors:  J R Mascola; M K Louder; T C VanCott; C V Sapan; J S Lambert; L R Muenz; B Bunow; D L Birx; M L Robb
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: analysis of immunological mimicry.

Authors:  K Lundin; A Samuelsson; M Jansson; J Hinkula; B Wahren; H Wigzell; M A Persson
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

7.  Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.

Authors:  S Munir Alam; Hua-Xin Liao; Georgia D Tomaras; Mattia Bonsignori; Chun-Yen Tsao; Kwan-Ki Hwang; Haiyan Chen; Krissey E Lloyd; Cindy Bowman; Laura Sutherland; Thomas L Jeffries; Daniel M Kozink; Shelley Stewart; Kara Anasti; Frederick H Jaeger; Robert Parks; Nicole L Yates; R Glenn Overman; Faruk Sinangil; Phillip W Berman; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Nicos Karasavva; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Susan Zolla-Pazner; Sampa Santra; Norman L Letvin; Stephen C Harrison; Barton F Haynes
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

8.  Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.

Authors:  Moumita Dutta; Jun Liu; Kenneth H Roux; Kenneth A Taylor
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

Review 9.  The antigenicity of tobacco mosaic virus.

Authors:  M H Van Regenmortel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-03-29       Impact factor: 6.237

10.  Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody.

Authors:  J S McDougal; M S Kennedy; S L Orloff; J K Nicholson; T J Spira
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.